EVT-401 / Evotec, Conba - LARVOL DELTA

Antagonism of P2X7 receptor function in synovial fibroblasts is a potential therapeutic manipulation in rheumatoid arthritis. (PubMed, Purinergic Signal) - "In humanized animal models of RA, EVT-401 demonstrated therapeutic efficacy, exerting direct anti-invasive and cartilage-protective effects on RA SFs. In conclusion, inhibition of P2X7R function in synovial fibroblasts may represent a promising therapeutic approach for patients with drug-refractory RA."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Osteoarthritis • Pain • Rheumatoid Arthritis • Rheumatology • IL6

P2X7R of synovial fibroblasts is a potential therapeutic target associated with refractory rheumatoid arthritis. (PubMed, Sci Adv) - "Furthermore, we demonstrated that EVT-401 markedly reduced synovial inflammation and arthritis severity in a nonhuman primate model of autoimmune arthritis. Together, these findings suggest that P2X7R is involved in synovial inflammation and its inhibition may represent a potential therapeutic strategy for refractory RA."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Identification and characterization of related substances in EVT-401 by hyphenated LC-MS techniques. (PubMed, J Pharm Anal) - "Fourteen RSs including six process-related substances and eight degradation products were detected and identified in EVT-401 with positive ESI high-resolution TOF-MS analysis of their parent ions and the corresponding product mass spectra elucidation, and some of them were further verified by chemical synthesis and NMR spectroscopy. The specific LC-MS method developed for separation, identification and characterization of RSs is valuable for EVT-401 manufacturing process optimization and quality control."

Journal • Biosimilar • Multiple Sclerosis

Evotec H1 2012: Building innovation on the back of profitable growth (Globenewswire) - Evotec partnered in China with Conba especially for inflammation and endometriosis pain in April 2012 for EVT 401 a P2X7 antagonist

Licensing / partnership • Pain